Affiliation:
1. Department of Microbiology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories
2. Tuberculosis and Chest Unit, Grantham Hospital, Aberdeen, Hong Kong, China
Abstract
ABSTRACT
A new strategy known as multiplex PCR amplimer conformation was developed for detection of mutation in the
gyrA
gene of 138 clinical isolates of
Mycobacterium tuberculosis
. The method generated a single-stranded and heteroduplex DNA banding pattern of multiplex PCR amplimers of the region of interest that was extremely sensitive to specific mutations, thus enabling much more sensitive and reliable mutation analysis compared to the standard single-stranded conformation polymorphism technique. The genetic profiles of the
gyrA
gene of the 138 isolates as detected by MPAC were confirmed by nucleotide sequencing and were found to correlate strongly with the in vitro susceptibilities of the mutant strains to six fluoroquinolones (ofloxacin, levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, and sitafloxacin). All 32 isolates that contained
gyrA
mutations exhibited cross-resistance to the six fluoroquinolones (ofloxacin MIC for 90% of strains > 16 mg/liter), although moxifloxacin, gatifloxacin, and sitafloxacin (MIC for 90% of strains ≤ 4 mg/liter) were apparently more active than ofloxacin, levofloxacin, and sparfloxacin (MIC for 90% of strains ≥ 16 mg/liter). All
gyrA
mutations were clustered in codons 90, 91, and 94, and aspartic acid 94 was most frequently mutated. Twenty-three isolates without
gyrA
mutations were also found to exhibit reduced susceptibility to ofloxacin (MIC for 90% of strains = 4 mg/liter), but largely remained susceptible to other drugs (MIC for 90% of strains ≤ 1 mg/liter). Another 83 isolates without mutations were fully susceptible to all six fluoroquinolones (ofloxacin MIC for 90% of strains = 1 mg/liter). In conclusion, high-level phenotypic resistance to fluoroquinolones among
M. tuberculosis
clinical isolates, which appears to be predominantly due to
gyrA
mutations, may be readily detected by genotyping techniques such as multiplex PCR amplimer conformation.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference35 articles.
1. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients
2. Canetti, G., F. Wallace, A. Khomenko, H. Mahler, N. Menon, D. Mitchison, N. Rist, and N. Smelev. 1969. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull. W.H.O.41:21-43.
3. Fluoroquinolone Action against Mycobacteria: Effects of C-8 Substituents on Growth, Survival, and Resistance
4. Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of
Mycobacterium bovis
BCG and
Staphylococcus aureus
5. Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates of
Mycobacterium tuberculosis
Cited by
118 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献